Management options for Takayasu arteritis

Bibliography

• Kerr GS. Takayasu arteritis. Ann Intern Med 1994;120(11):919-29
   PubMed Web of Science ®Google Scholar
• Mason JC. Takayasu arteritis--advances in diagnosis and management. Nat Rev Rheumatol 2010;6(7):406-15
   PubMed Web of Science ®Google Scholar
• Ogino H, et al. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 2008;118(25):2738-47
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon K, Clark et al. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56(3):1000-9
   PubMed Web of Science ®Google Scholar
• Freitas DS, et al. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012;32(3):703-9
   PubMed Web of Science ®Google Scholar
• Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels Suppl 1992;7:11-17
   PubMedGoogle Scholar
• Seko Y, et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J Clin Invest 1994;93(2):750-8
   PubMed Web of Science ®Google Scholar
• Weyand CM, et al. Medium- and large-vessel vasculitis. N Engl J Med 2003;349(2):160-9
   PubMed Web of Science ®Google Scholar
• Mwipatayi BP, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 2005;75(3):110-17
   PubMed Web of Science ®Google Scholar
• Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu's disease). Circulation 1989;80(3):429-37
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994;90(4):1855-60
   PubMed Web of Science ®Google Scholar
• Sharma BK, et al. Takayasu arteritis in India. Heart Vessels Suppl 1992;7:37-43
   PubMedGoogle Scholar
• Park M.C, et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 2005;34(4):284-92
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007;33(4):777-86, vi
   PubMed Web of Science ®Google Scholar
• Cong X.L, et al. Takayasu's arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol 2010;29(9):973-81
   PubMed Web of Science ®Google Scholar
• Lee G.Y, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol 2012;159(1):14-20
   PubMed Web of Science ®Google Scholar
• Soto M.E, et al. Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol 2008;26(3 Suppl 49):S9-15
   PubMed Web of Science ®Google Scholar
• Arnaud L. et al. Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore) 2010;89(1):1-17
   PubMed Web of Science ®Google Scholar
• Manfredi A.A, et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008;20(5):538-44
   PubMed Web of Science ®Google Scholar
• Baldini M, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 2012;64(3):854-65
   PubMedGoogle Scholar
• Dagna L, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155(7):425-33
   PubMed Web of Science ®Google Scholar
• Willis M.S, et al. Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 2010;106(3):463-78
   PubMed Web of Science ®Google Scholar
• Maugeri N, et al. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res 2012;129(3):267-73
   PubMed Web of Science ®Google Scholar
• Mavrogeni S, et al. The role of multimodality imaging in the evaluation of Takayasu arteritis. Semin Arthritis Rheum 2013;42(4):401-12
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68(3):318-23
   PubMed Web of Science ®Google Scholar
• Ishikawa K. Effects of prednisolone therapy on arterial angiographic features in Takayasu's disease. Am J Cardiol 1991;68(4):410-13
   PubMed Web of Science ®Google Scholar
• Vanoli M, et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 2005;53(1):100-7
   PubMed Web of Science ®Google Scholar
• Bicakcigil M, et al. Takayasu's arteritis in Turkey - clinical and angiographic features of 248 patients. Clin Exp Rheumatol 2009;27(1 Suppl 52):S59-64
   PubMed Web of Science ®Google Scholar
• Hoffman G.S, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37(4):578-82
   PubMed Web of Science ®Google Scholar
• Valsakumar A.K, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003;30(8):1793-8
   PubMed Web of Science ®Google Scholar
• Shinjo SK, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 2007;26(11):1871-5
   PubMed Web of Science ®Google Scholar
• Daina E A, et al. Remuzzi, Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999;130(5):422-6
   PubMed Web of Science ®Google Scholar
• Shelhamer JH, et al. Takayasu's arteritis and its therapy. Ann Intern Med 1985;103(1):121-6
   PubMed Web of Science ®Google Scholar
• de Souza AW, et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012;41(3):227-30
   PubMed Web of Science ®Google Scholar
• Horigome H, Kamoda T, Matsui A. Treatment of glucocorticoid-dependent Takayasu's arteritis with cyclosporin. Med J Aust 1999;170(11):566
   PubMed Web of Science ®Google Scholar
• Matsuyama A, et al. Minocycline for the treatment of Takayasu arteritis. Ann Intern Med 2005;143(5):394-5
   PubMed Web of Science ®Google Scholar
• Park MC, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006;45(5):545-8
   PubMed Web of Science ®Google Scholar
• Hoffman GS, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50(7):2296-304
   PubMed Web of Science ®Google Scholar
• Molloy ES, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67(11):1567-9
   PubMed Web of Science ®Google Scholar
• Schmidt J, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 2012;64(7):1079-83
   PubMed Web of Science ®Google Scholar
• Mekinian A, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: french multicentre study. Rheumatology (Oxford) 2012;51(5):882-6
   PubMed Web of Science ®Google Scholar
• Quartuccio L, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012;30(6):922-8
   PubMed Web of Science ®Google Scholar
• Comarmond C, et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012;11(9):678-84
   PubMed Web of Science ®Google Scholar
• Noris M, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100(1):55-60
   PubMed Web of Science ®Google Scholar
• Seitz M, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156
   PubMed Web of Science ®Google Scholar
• Salvarani C, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012;30(1 Suppl 70):S90-3
   PubMed Web of Science ®Google Scholar
• Unizony S, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012;64(11):1720-9
   PubMed Web of Science ®Google Scholar
• Salvarani C, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012;51(1):151-6
   PubMed Web of Science ®Google Scholar
• Bredemeier M, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;30(1 Suppl 70):S98-100
   PubMed Web of Science ®Google Scholar
• Xenitidis T, et al. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 2013
   PubMed Web of Science ®Google Scholar
• Tombetti et al. Treatment of refractory Takayasu arteritis with tocilizumab: seven Italian patients from a single referral Center. J Rheumatology 2013; 40(12): doi:10.3899/jrheum.130536
   PubMed Web of Science ®Google Scholar
• Hoyer BF, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012;71(1):75-9
   PubMed Web of Science ®Google Scholar
• Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis. ClinicalTrials.gov: NCT00556439
   Google Scholar
• Seyahi E, et al. Aortic and coronary calcifications in Takayasu arteritis. Semin Arthritis Rheum 2013
   PubMed Web of Science ®Google Scholar
• Seyahi E, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006;65(9):1202-7
   PubMed Web of Science ®Google Scholar
• de Souza AW, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010;74(6):1236-41
   PubMed Web of Science ®Google Scholar
• Nesher G, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50(4):1332-7
   PubMedGoogle Scholar
• Maugeri N, et al. Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks? Autoimmunity 2009;42(4):386-8
   PubMed Web of Science ®Google Scholar
• Hoes JN, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66(12):1560-7
   PubMed Web of Science ®Google Scholar
• Grossman JM, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62(11):1515-26
   PubMed Web of Science ®Google Scholar
• van Assen S, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70(3):414-22
   PubMed Web of Science ®Google Scholar
• Bijl M, et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012;11(8):572-6
   PubMed Web of Science ®Google Scholar
• Maugeri N, et al. Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol 2009;156(3):395-404
   PubMed Web of Science ®Google Scholar
• Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005;17(1):16-24
   PubMed Web of Science ®Google Scholar
• Tyagi S, et al. Early and long-term results of subclavian angioplasty in aortoarteritis (Takayasu disease): comparison with atherosclerosis. Cardiovasc Intervent Radiol 1998;21(3):219-24
   PubMed Web of Science ®Google Scholar
• Tyagi S, et al. A decade of subclavian angioplasty: aortoarteritis versus atherosclerosis. Indian Heart J 1996;48(6):667-71
   PubMedGoogle Scholar
• Joseph S, et al. Percutaneous transluminal angioplasty of the subclavian artery in nonspecific aortoarteritis: results of long-term follow-up. J Vasc Interv Radiol 1994;5(4):573-80
   PubMed Web of Science ®Google Scholar
• Sharma S, et al. Renal artery stenosis caused by nonspecific arteritis (Takayasu disease): results of treatment with percutaneous transluminal angioplasty. AJR Am J Roentgenol 1992;158(2):417-22
   PubMed Web of Science ®Google Scholar
• Sharma S, et al. Results of renal angioplasty in nonspecific aortoarteritis (Takayasu disease). J Vasc Interv Radiol 1998;9(3):429-35
   PubMed Web of Science ®Google Scholar
• Lee BB, et al. Endovascular management of takayasu arteritis: is it a durable option? Vascular 2009;17(3):138-46
   PubMed Web of Science ®Google Scholar
• Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol 2004;31(1):102-6
   PubMed Web of Science ®Google Scholar
• Park MC, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford) 2006;45(5):600-5
   PubMed Web of Science ®Google Scholar
• Saadoun D, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012;125(6):813-19
   PubMed Web of Science ®Google Scholar
• Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003;349(9):829-30
   PubMed Web of Science ®Google Scholar
• Mancini D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108(1):48-53
   PubMed Web of Science ®Google Scholar
• Eisen HJ, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349(9):847-58
   PubMed Web of Science ®Google Scholar
• Nordmann AJ, et al. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials. Eur Heart J 2004;25(1):69-80
   PubMed Web of Science ®Google Scholar
• Sharma BK, et al. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol 2000;75(Suppl 1):S147-52
   PubMedGoogle Scholar
• Stone GW, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356(10):998-1008
   PubMed Web of Science ®Google Scholar
• Qureshi MAZ, Martin RK. Greenberg, Endovascular management of patients with Takayasu arteritis: stents versus stent grafts. Semin Vasc Surg 2011;24(1):44-52
   PubMed Web of Science ®Google Scholar
• Miyata T, et al. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation 2003;108(12):1474-80
   PubMed Web of Science ®Google Scholar
• Weaver FA, Yellin AE. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl 1992;7:154-8
   PubMedGoogle Scholar
• Weaver FA, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg 2004;39(4):749-57
   PubMed Web of Science ®Google Scholar
• Kim YW, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg 2012;55(3):693-700
   PubMed Web of Science ®Google Scholar
• Fields CE, et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg 2006;43(1):64-71
   PubMed Web of Science ®Google Scholar
• Pajari R, Hekali P, Harjola PT. Treatment of Takayasu's arteritis: an analysis of 29 operated patients. Thorac Cardiovasc Surg 1986;34(3):176-81
   PubMed Web of Science ®Google Scholar
• Feng R, et al. Aortorenal bypass with autologous saphenous vein in Takayasu arteritis-induced renal artery stenosis. Eur J Vasc Endovasc Surg 2011;42(1):47-53
   PubMed Web of Science ®Google Scholar
• Miyata T, et al. Anastomotic aneurysms after surgical treatment of Takayasu's arteritis: a 40-year experience. J Vasc Surg 1998;27(3):438-45
   PubMed Web of Science ®Google Scholar
• Erdogan A, et al. PTFE patching to prevent anastomotic aneurysm formation in Takayasu's arteritis. Eur J Vasc Endovasc Surg 2003;25(5):478-80
   PubMed Web of Science ®Google Scholar